<DOC>
	<DOCNO>NCT00695019</DOCNO>
	<brief_summary>The purpose study determine whether lozenge interferon-alpha dissolve mouth prevent relapse patient hepatitis C virus infection complete virologic response receive combination inject interferon-alpha oral ribavirin .</brief_summary>
	<brief_title>Interferon-alpha Lozenges Prevention Relapse Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HCV genotype 1b Will complete pegylated IFNalpha ribavirin therapy within 4 week Serum HCV RNA negative within 4 week study entry ChildPugh score B C Decompensated liver function History malignancy within past 5 year Other cause liver disease besides HCV infection Uncontrolled diabetes hypertension Unwilling use two form birth control study treatment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Prevention Relapse</keyword>
	<keyword>HCV genotype 1b</keyword>
	<keyword>Recurrence</keyword>
</DOC>